Phaseline

Targets › KIF18A

KIF18A (Kinesin-like protein KIF18A): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Apr 2027.

Microtubule-depolymerizing kinesin which plays a role in chromosome congression by reducing the amplitude of preanaphase oscillations and slowing poleward movement during anaphase, thus suppressing chromosome movements. May stabilize the CENPE-BUB1B complex at the kinetochores during early mitosis and maintains CENPE levels at kinetochores during chromosome congression. (UniProt, Q8NI77)

Open in Phaseline: the race on KIF18A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Accent TherapeuticsATX-295
KIF18A inhibitor
KIF18APhase 1Advanced Solid TumorsApr 2027
Suzhou Genhouse Bio Co., Ltd.GH2616
KIF18A inhibitor
KIF18APhase 1Advanced Solid Tumor CancerDec 2028

Conditions

Advanced Solid Tumors (1) Advanced Solid Tumor Cancer (1)

Modalities

mixed (1), small molecule (1)

Companies

Accent Therapeutics (1) Suzhou Genhouse Bio Co., Ltd. (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.